Edition:
United States

Immunomedics Inc (IMMU.O)

IMMU.O on Consolidated Issue listed on NASDAQ Global Market

6.83USD
29 Mar 2017
Change (% chg)

-- (--)
Prev Close
$6.83
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
3,226,381
52-wk High
$7.15
52-wk Low
$1.95

IMMU.O

Chart for IMMU.O

About

Immunomedics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized... (more)

Overall

Beta: 1.67
Market Cap(Mil.): $724.52
Shares Outstanding(Mil.): 106.08
Dividend: --
Yield (%): --

Financials

  IMMU.O Industry Sector
P/E (TTM): -- 49.04 30.15
EPS (TTM): -0.72 -- --
ROI: -152.84 -2.17 13.05
ROE: -- 5.20 14.20

BRIEF-Seattle Genetics says court issued temporary restraining order enjoining taking action in furtherance of closing of license agreement with Immunomedics

* Seattle Genetics- On March 9,court issued temporary restraining order enjoining taking action in furtherance of closing of license agreement with Immunomedics

Mar 10 2017

BRIEF-VenBio issues statement to Immunomedics stockholders

* Venbio select advisor llc says issued statement to immunomedics stockholders

Mar 02 2017

BRIEF-Immunomedics outlines revised settlement offer rejected by venBio

* Immunomedics outlines revised settlement offer rejected by venBio; announces actions that are in the best interests of all stockholders

Mar 02 2017

BRIEF-Immunomedics files federal lawsuit against venBio for continuing material violations of federal securities laws

* Immunomedics - filed a federal lawsuit and a motion seeking injunctive relief against venbio select advisor llc and venbio's four director candidates

Feb 21 2017

BRIEF-Immunomedics sends letter to stockholders highlighting global licensing agreement

* Immunomedics sends letter to stockholders highlighting value creating global licensing agreement, underscoring fulfillment of promise to stockholders Source text for Eikon: Further company coverage:

Feb 15 2017

BRIEF-Immunomedics issued statement in response to lawsuit filed on Feb. 13 by Venbio Select Advisor

* Immunomedics inc - issued statement in response to lawsuit filed on february 13, 2017 by venbio select advisor llc

Feb 14 2017

BRIEF-VenBio "intends to evaluate all of its legal options" on Immunomedics partnership deal

* venBio Select Advisor LLC - beneficial owner of approximately 10.5 million shares, or 9.9 percent, of Immunomedics Inc

Feb 10 2017

Immunomedics in $2 bln licensing deal with Seattle Genetics

Drug developer Immunomedics Inc said on Friday it entered into a development and licensing deal worth up to $2 billion for its experimental cancer drug with Seattle Genetics Inc.

Feb 10 2017

UPDATE 3-Immunomedics in $2 bln licensing deal with Seattle Genetics

* Seattle Genetics' stock down 4 pct (Adds details from conf call, recasts; updates shares)

Feb 10 2017

BRIEF-Immunomedics announces postponement of 2016 annual meeting

* Annual meeting has been postponed to march 3, 2017 at 10:00 a.m. Eastern time

Feb 10 2017

More From Around the Web

Competitors

Earnings vs. Estimates